LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) has filed its Monthly Return for Equity Issuer for the period ended 30 September 2026, confirming a stable capital structure and full compliance with Hong Kong listing requirements.

Key disclosures are as follows:

• Authorised and issued share capital unchanged – Authorised/registered share capital stood at RMB 76.32 million, comprising 75.06 million H shares and 1.26 million unlisted shares, each with a par value of RMB 1. – No new shares were issued, cancelled, or repurchased during September. Consequently, the total issued share count remained at 76.32 million, with zero treasury shares on record.

• Public float fully meets listing rules – The company reconfirmed compliance with the Main Board’s minimum public float threshold. The free-float requirement is 21.05 % of issued H shares (excluding treasury shares), and LongBio Pharma indicated it satisfied this level as at 30 September 2026.

• No outstanding equity instruments – The filing shows no share options, warrants, convertible securities, or other agreements that could dilute current shareholders.

• Governance confirmations – The board affirmed that all regulatory, legal, and listing-rule obligations related to the company’s securities have been met, and no transactions requiring additional disclosure occurred during the month.

With the share capital static and regulatory compliance maintained, LongBio Pharma’s equity profile enters the final quarter of 2026 unchanged, providing investors with continuity in the company’s issued-share base and float composition.